

Fig. S3 Multivariate analysis of the predictive factors for TFS

Results of the multivariate analysis for TFS

Factor	Hazard ratio	p-value
Duration of TKI (<u>≤90months</u>)	1.51 (0.40–4.86)	0.49
Gender (male)	1.42 (0.35–5.75)	0.63
Total dose of dasatinib (>72600mg)	1.12 (0.33–3.77)	0.85
CD3-CD56+ NK (<u>>41%</u>)	5.21 (1.50–10.05)	0.0093